We are now completely out of stock of Xenical and Orlistat. We are making enquiries as to whether or not we will be able to acquire further stock in the next few days. You may still register with us but we will not be able to issue any prescriptions until stocks are replenished.
If you have any questions about this matter, please do not hesitate to get in touch with us. If you are already registered with us, we will update you by e-mail when new stock arrives. To get the latest information on our Xenical orlistat stock situation, please click here and you will be directed to our Xenical news feed.
Financial market data powered by Quotemedia. All rights reserved. Rate votes Share. Comments Name Required. Email Required, but never displayed.
Submit Submit. Karen H. I know from Chromadex's point of view they would like to be considered part of the conversation. I'm not quite sure that the consumer is heading full fledged towards non-FDA approved drugs at least not yet.
I think Chromadex's BlueLine products are well marketed, I'm just not sure if consumers consider natural solutions as doing the same job as FDA approved drugs. I'll have to research Chromadex more. Save to My Collection. In My Collection [remove]. This article is interesting and I think the winners in this competition are going to be big winners.
I'm still uncertain as to how the market will shake out. If I were companies going after FDA approval, I would be concerned about the threat Chromadex represents as mentioned in the other posts. On the other hand, there are certainly those groups that love a paternalistic government. I'm thinking I'll place my bets on Chromadex, largely because I think their solutions do seem more in line with the future of pharmaceutical consumption.
This is to all you Chromadex followers: I agree that there's a lot of upside to Chromadex and some pretty heavy hitters who own the stock, but the company is still losing money. They're announcement in the next couple of weeks better be very good, or I think the company will run into market disillusionment.
Chromadex is good at advertising, but so are its competitors in the natural supplements business Pfizer, GNC, Weight Watchers. I think Chromadex needs to do some better consumer oriented advertising. Sickeningthis commented 9 years ago tags: PFE. Instead, the fat passes through the body to the gastrointestinal tract until it is excreted. These medications also block fat-soluble vitamins including vitamins A, B, and K. However, according to Dr.
Donald Hensrud, associate professor of nutrition and preventive medicine at the Mayo Clinic in Rochester, Minn. More severe side effects reported to the FDA include liver disease, pancreatitis, and kidney stones.
The FDA received 47 reports of acute pancreatitis and 73 cases of kidney stones attributed to orlistats. While many experts say these side effects are rare, it's not clear what segment of people who use the drug may experience these severe conditions. Monique Paulwell of Bowie, Md.
We can only declare a winner when one of them hits sales of a billion dollars annually, which is the hurdle for being labeled a blockbuster drug. Rather than trying to figure out which company will eventually win, the best move for investors interested in this space might be to buy both, especially since the two initially won't compete directly.
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Average returns of all recommendations since inception. Cost basis and return based on previous market day close. Investing Best Accounts. Stock Market Basics. Stock Market. Industries to Invest In. Getting Started. Planning for Retirement.
0コメント